## GS: The Goldman Sachs Group, Inc. - XLF: Financial Services

### Executive Summary

VALUE thesis: PEG 1.29 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($813.46)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Form FWP GOLDMAN SACHS GROUP INC Filed by: GOLDMAN SACHS GROUP INC**
- Source: StreetInsider | 20251204T071009 | Neutral | Relevance: 100%
- This document is a Free Writing Prospectus (FWP) filed by Goldman Sachs Group Inc. concerning "Market Linked Securities — Auto-Callable with Leveraged Upside Participation and Fixed Percentage Buffered Downside Principal at Risk Securities" linked to the iShares® MSCI Emerging Markets ETF, due January 4, 2029. It outlines the terms, hypothetical payout profiles, and significant risks associated with this investment, including a summary of underwriting discounts and the estimated value of the securities. Investors are advised to read related documents for full information.

**2. Goldman Is Pitching a Risky $500 Million Deal to Finance Shareholder Payout**
- Source: Bloomberg.com | 20251203T214200 | Neutral | Relevance: 100%
- A Canadian benefits provider owned by Goldman Sachs Group Inc. is seeking approximately $500 million from private credit lenders. This financing, in the form of a payment-in-kind (PIK) note tied to a holding company, is intended to fund a payout to shareholders. The structure allows the company to defer paying interest in cash.

**3. Halozyme Therapeutics (NASDAQ:HALO) Receives Sell Rating from The Goldman Sachs Group**
- Source: MarketBeat | 20251205T140831 | Somewhat-Bullish | Relevance: 93%
- The Goldman Sachs Group reiterated a "sell" rating on Halozyme Therapeutics (NASDAQ:HALO) with a $56 price target, indicating a potential 13.39% downside. Despite this, Halozyme recently surpassed quarterly earnings and revenue estimates, showing strong profitability. Analyst coverage for Halozyme is mixed, with an average rating of "Hold" and an average target price of $75.10.

**4. Prudential Financial Names Matt Armas CIO**
- Source: Chief Investment Officer | 20251203T225126 | Neutral | Relevance: 87%
- Prudential Financial Inc. has appointed Matt Armas as CIO and senior vice president, effective March 12, 2026. Armas, currently global co-head of insurance at Goldman Sachs Asset Management, will succeed Tim Schmidt, who is retiring. His extensive insurance and investment expertise were key factors in the appointment, according to Prudential Financial CEO Andrew Sullivan.

**5. Symbotic Announces Pricing of Primary and Secondary Offering of Class A Common Stock**
- Source: The Manila Times | 20251205T160926 | Somewhat-Bullish | Relevance: 84%
- Symbotic Inc. announced the pricing of a primary and secondary underwritten public offering of 10,000,000 shares of its Class A common stock at $55.00 per share. The company will sell 6,500,000 shares for general corporate purposes, while an affiliate of SoftBank Group Corp. will sell 3,500,000 shares. The offering is expected to close on December 8, 2025.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 6 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.5% (-1.5%)
- Blackrock Inc.: 7.7% (+0.1%)
- State Street Corpora: 6.4% (-1.5%)
- JPMORGAN CHASE & CO: 4.7% (+99.2%)
- Morgan Stanley: 2.6% (-7.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +3.3% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.29 suggests fair value with growth premium. Quality metrics strong (margin 29%). Balance sheet: $2.1B free cash flow. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $274.6B |
| Beta | 1.35 |
| 52W Range | $439.38 - $919.10 |
| Short Interest | 2.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.29 |
| Forward P/E | 15.5 |
| Current P/E | 17.5 |
| YoY Growth | 13.5% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from 0.8% to 4.2% (+3.3% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 80th percentile. MRS_5 at 2.4% confirms short-term momentum alignment. AM_20 at 6.5% shows strong absolute momentum above own 20MA. Outperforming sector by 4.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (5.47), confirming momentum. OFD pattern: +FTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.15% (CS: 81) | Strong |
| RSI_14 | 67.4 | Neutral |
| MACD Histogram | 5.47 | Bullish |
| vs SMA20 | 1.061x | Above |
| vs SMA50 | 1.082x | Above |
| vs SMA200 | 1.257x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $854.56
- **Stop Loss:** $813.46 (4.8% risk)
- **Target:** $936.76 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 24
- **Position Value:** $20,509.44
- **Portfolio %:** 20.51%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-01-15 (Est: $11.51)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $11.09 | $12.25 | +10.5% |
| 2025Q2 | $9.66 | $10.91 | +12.9% |
| 2025Q1 | $12.26 | $14.12 | +15.2% |
| 2024Q4 | $8.35 | $11.95 | +43.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*